School of Medicine
Showing 1-39 of 39 Results
-
Steven Artandi
Laurie Kraus Lacob Director of the Stanford Cancer Institute (SCI), Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly InterestsTelomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
-
Ami Bhatt
Associate Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
-
Linda Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor
Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.
-
Rondeep Brar
Clinical Associate Professor, Medicine - Hematology
BioI aim to provide high quality care in a diverse patient practice. My clinic includes all types of hematologic disorders, ranging from anemia, clotting/bleeding disorders, and low blood counts to complex malignancies such as leukemia, myelodysplastic syndrome, myeloma, and lymphoma. I aim to combine the efficiency of a private office with the complex care expected of a tertiary institution like Stanford. I value your time and strive to maintain an on-schedule clinic.
As the interim medical co-director of the Stanford Cancer Center, it is my privilege to partner with my colleagues in advancing innovative research alongside high quality, coordinated, and compassionate care for our patients. -
Robert Diep
Clinical Assistant Professor, Medicine - Hematology
BioDr. Diep specializes in the treatment of patients with conditions considered as nonmalignant hematology, which includes hemoglobinopathies, bleeding/clotting disorders, and disorders affecting blood counts.
His practice style emphasizes the patient-physician relationship, the best available evidence, and the patients' values as anchors for a shared decision-making process. He is passionate about medical education and is dedicated to improving the care delivery for patients with blood disorders. -
Lawrence Tim Goodnough
Professor of Pathology and of Medicine (Hematology)
Current Research and Scholarly InterestsImproving blood utilization
Promoting alternatives to blood transfusion
Quality improvements -
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Neel K. Gupta
Clinical Assistant Professor, Medicine - Oncology
Clinical Assistant Professor, Medicine - HematologyCurrent Research and Scholarly InterestsI have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.
-
Marie Hollenhorst, MD, PhD
Clinical Instructor, Pathology
Clinical Instructor, Medicine - HematologyBioDr. Hollenhorst is a physician and scientist with expertise in non-malignant hematology, transfusion medicine, and chemical biology. Dr. Hollenhorst values the one-on-one relationships that she forms with her patients, and strives to deliver the highest quality of care for individuals with blood diseases. Her experience caring for patients drives her to ask scientific questions in the laboratory, where she aims to bring a chemical approach to the study of non-malignant blood disease.
Dr. Hollenhorst pursued combined MD and PhD training at Harvard University, where she received a PhD in Chemical Biology under the mentorship of Professor Christopher T Walsh. She subsequently completed a residency in Internal Medicine at Brigham and Women's Hospital, a fellowship in Transfusion Medicine at Harvard Medical School, and a fellowship in Hematology at Stanford.
Dr. Hollenhorst has an interest in the biology of platelets, which are cellular fragments that help the blood to maintain a healthy balance between bleeding and clotting. Working in the laboratory of Professor Carolyn Bertozzi of Stanford Chemistry, Dr. Hollenhorst is studying sugar molecules found on the surface of platelets that are important in controlling their function and lifespan.
Dr. Hollenhorst's research is supported by an NIH K99 Career Pathway to Independence in Blood Science Award for Physician-Scientists, a Stanford Chemistry, Engineering & Medicine for Human Health Physician-Scientist Fellowship, and a National Blood Foundation Early-Career Scientific Research Grant. -
David Iberri
Clinical Assistant Professor, Medicine - Hematology
BioDr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.
-
Calvin Kuo
Maureen Lyles D'Ambrogio Professor
Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Lee Levitt
Professor of Medicine (Hematology) at the Santa Clara Valley Medical Center, Emeritus
Current Research and Scholarly InterestsLow molecular-weight heparins Clinical trials with anti-thrombotics Clinical trials in patients with leukemia, breast cancer and myeloma Medical education.
-
Michaela Liedtke
Associate Professor of Medicine (Hematology)
Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis
4) Characterization of the molecular mechanism of MLL-induced acute leukemia -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.
Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
1) normal and pathologic immunity and immunotherapy
2) cancer biology
3) normal and malignant hematopoiesis -
Ravindra Majeti MD, PhD
RZ Cao Professor
Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
-
Gabriel Mannis
Assistant Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.
-
Bruno Medeiros
Adjunct Clinical Associate Professor, Medicine - Hematology
Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
-
William Shomali
Clinical Assistant Professor, Medicine - Hematology
BioDr. Shomali is a clinical assistant professor of Hematology at Stanford University School of Medicine. He is board certified in hematology & medical oncology.
Dr. Shomali specializes in the treatment of blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes. He aims to provide compassionate, personalized, and evidence-based care to each patient.
Dr. Shomali received his medical degree from the University of Jordan, followed by a postdoctoral fellowship at MD Anderson Cancer Center where he studied infections in cancer patients and the role of biomarkers in defining tumor fever. He completed his residency training in Internal Medicine at the Cleveland Clinic Foundation where he served as a Chief Medical Resident. He then joined Stanford University for his combined Hematology & Oncology fellowship training.
Dr. Shomali’s research interests include the study of novel agents in myeloproliferative neoplasms and myelodysplastic syndromes. He developed investigator-initiated clinical trials for patients with eosinophilic neoplasms and advanced myelofibrosis. In addition, he co-authored several papers and book chapters discussing the care of patients with cancer. His work has been presented in national meetings and published in peer reviewed journals including Blood, American Journal of Hematology, British Journal of Hematology, Leukemia & Lymphoma, and Cancer.
Among his honors, Dr. Shomali received the Cleveland Clinic Excellence in Teaching Award and was named to the Alpha Omega Alpha Medical Honor Society. He has received a Young Investigator Award from the Conquer Cancer Foundation, an NIH Institutional National Research Service Award, and a Stanford Cancer Institute Fellowship Award.
Dr. Shomali is a member of the American Society of Hematology and the American Society of Clinical Oncology. -
James L. Zehnder, M.D.
Professor of Pathology (Research) and of Medicine (Hematology)
Current Research and Scholarly InterestsOur laboratory focuses on translational research in 2 main areas - genomic approaches to diagnosis and minimal residual disease testing for patients with cancer, and molecular basis of disorders of thrombosis and hemostasis. My clinical focus is in molecular pathology, diagnosis and treatment of disorders of hemostasis and thrombosis and general hematology.
-
Tian Yi Zhang, MD, PhD. https://www.thezhanglabstanford.com/
Assistant Professor of Medicine (Hematology)
BioDr. Zhang is a board-certified hematologist. She is also an assistant professor of hematology at Stanford University School of Medicine. In addition to her medical degree, she holds a PhD in cellular and molecular immunology.
In her clinical practice, she treats patients with all forms of hematological malignancies, offering specialized expertise in acute myeloid leukemia, including therapy-resistant cases. For each patient, she develops a personalized care plan encompassing novel treatment options.
Her research activities include conducting early phase clinical trials, investigator initiated clinical trials (IITs), studying the immune repertoire in patients with myeloid malignancies, and exploring cholesterol metabolic dependencies of acute myeloid leukemia (AML).
She was the recipient of an A.P. Giannini Foundation fellowship award, which supports innovative research. The award helped fund Dr. Zhang’s study of how AML cells interact with other cells in bone marrow. A significant finding confirmed that AML cells secrete a protein that suppresses the production of red blood cells, the same protein that causes inflammation in disorders such as rheumatoid arthritis and Crohn’s disease.
Her many other honors include the National Cancer Institute Career Development (K08) Award, the American Society of Hematology (ASH) Research Training Award for Fellows, Stanford Cancer Institute - American Cancer Society (SCI-ACS) Pilot Grant and Best ASH Abstract Award two years in a row. She also has earned recognition from the National Institutes of Health and American College of Physicians.
She has published her research findings on topics such as advanced therapy for high-risk myelodysplastic syndromes and reversal of bone marrow failure induced by AML. Her work has appeared in Leukemia & Lymphoma, Science Translational Medicine, Cancer Research, the Journal of Clinical Investigation, Journal of Immunology, and elsewhere.
Dr. Zhang is a member of the American Association of Cancer Research and American Society of Hematology. She advises and mentors Stanford medical students, residents and fellows. She delivers invited lectures to faculty and fellows. In addition, she has been an invited speaker on the topic of acute myeloid leukemia at the Association of Northern California Oncologists Update on Hematological Malignancies.
